Matthew Young
Scientist and coauthor on psychedelic and MDMA/psilocybin research publications
Data updated
Papers
Trials
Research Footprint
Matthew Young appears in 7 tracked papers (2015–2026), most studied alongside Psilocybin, MDMA and Placebo, across Depressive Disorders, Treatment-Resistant Depression (TRD) and PTSD.
Most-cited paper: 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning (134 citations).
Frequent co-authors: Guy Goodwin, Lindsey Marwood and Joyce Tsai.
Background & Research
Matthew B. Young is a researcher whose published work spans preclinical MDMA studies and clinical psilocybin research. His papers include seminal translational work on fear extinction and later studies on psilocybin outcomes in treatment-resistant depression, suggesting a role bridging basic neuroscience and psychiatric therapeutics.
Key Impact
He appears on multiple influential papers linking MDMA to fear extinction and psilocybin to treatment-resistant depression, including clinical and translational studies in psychedelic psychiatry.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Matthew Young is associated with.